In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor’s approval in the EU for patients with severe aortic stenosis who are at high or extreme surgical risk for open-heart surgery. Shots: Abbott has received CE Mark approval for its latest-generation transcatheter […]Read More
Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis Published: Sept 3, 2021 | Tags: Novartis, Cosentyx, secukinumab, NICE Recommendation, Plaque Psoriasis Pfizer […]Read More
Shots: The acquisition will accelerate Abbott’s vascular portfolio with the addition of Walk Vascular’s peripheral thrombectomy systems to treat patients with peripheral blood clots Walk Vascular’s JETi & JETi AIO peripheral thrombectomy systems are aspiration systems for the removal of intravascular clots. The systems are supported by RWE, and Walk is currently enrolling ~250 patients […]Read More
Shots: The head-to-head Amulet IDE study compares Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with the Watchman device to treat patients with AFib at an increased risk of stroke The study demonstrated superiority for the 1EPs of LAA (98.9% vs 96.8%) and was non-inferior for the co-primary safety & effectiveness endpoints Abbott’s Amulet Occluder with […]Read More
Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC Published: Aug 20, 2021 | Tags: Astellas, FibroGen, Evrenzo, Roxadustat, EC, Approval, Symptomatic Anemia, Chronic Kidney Disease Astellas and FibroGen’s Evrenzo (roxadustat) Receive EC’s Approval for Symptomatic Anemia Associated with Chronic Kidney Disease Published: Aug 20, 2021 […]Read More
Medtronic to Acquire Intersect ENT for ~$1.1B Published: Aug 6, 2021 | Tags: Medtronic, Intersect ENT, ~$1.1B Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer Published: Aug 6, 2021 | Tags: Kite, Appia, Allogeneic Cell Therapies, Cancer Polpharma & Bioeq Report BLA Submission to the US […]Read More
Shots: Abbott launches its latest Jot Dx ICM with new features to help clinicians for a constant flow of heart rhythm data to treat atrial fibrillation Jot Dx ICM allows 24/7 heart monitoring and connects directly with Abbott’s myMerlin smartphone app. The technology is designed to provide remote detection and improved diagnostic accuracy of cardiac […]Read More
The extraordinary demand for COVID-19 testing kits that were seen in 2020 and is yet to subside in 2021 resulted in many of the world’s biggest diagnostics companies being thrust into the limelight Siemens Healthineers, GE Healthcare, Roche, and Abbott are the top players in the race of the global diagnostic companies. The companies are […]Read More
BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Published: May 21, 2021 | Tags: BeiGene, Tislelizumab, CT, P-III, RATIONALE 309 Study, Recurrent, Metastatic Nasopharyngeal Cancer Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR […]Read More
The medical devices industry is a fast-growing market driven by the complex needs of patients encouraging life science companies to develop innovative therapies to improve health and QoL In 2020, the companies have shown growth resulted from a rise in the number of healthcare facilities, healthcare expenditure, technological advancements. Medtronic remains at the top of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
